Epstein-Barr virus ensures B cell survival by uniquely modulating apoptosis at early and late times after infection
- Duke University School of Medicine, United States
- Imperial College London, United Kingdom
- Harvard Medical School, United States
- University of Wisconsin School of Medicine and Public Health, United States
- Duke University, United States
Abstract
Latent Epstein-Barr virus (EBV) infection is causally linked to several human cancers. EBV expresses viral oncogenes that promote cell growth and inhibit the apoptotic response to uncontrolled proliferation. The EBV oncoprotein LMP1 constitutively activates NFB and is critical for survival of EBV-immortalized B cells. However, during early infection EBV induces rapid B cell proliferation with low levels of LMP1 and little apoptosis. Therefore, we sought to define the mechanism of survival in the absence of LMP1/NFB early after infection. We used BH3 profiling to query mitochondrial regulation of apoptosis and defined a transition from uninfected B cells (BCL-2) to early-infected (MCL-1/BCL-2) and immortalized cells (BFL-1). This dynamic change in B cell survival mechanisms is unique to virus-infected cells and relies on regulation of MCL-1 mitochondrial localization and BFL-1 transcription by the viral EBNA3A protein. This study defines a new role for EBNA3A in the suppression of apoptosis with implications for EBV lymphomagenesis.
Data availability
-
EBNA2 ChIP-SeqPublicly available at the NCBI Gene Expression Omnibus (accession no: GSE29498).
-
The NF-kB genomic landscape in lymphoblastoid B-cellsPublicly available at the NCBI Gene Expression Omnibus (accession no: GSE55105).
-
EBNA3C ChIP-SeqPublicly available at the NCBI Gene Expression Omnibus (accession no: GSE52632).
-
EBNA3A ChIP-SeqPublicly available at the NCBI Gene Expression Omnibus (accession no: GSE59181).
-
Histone modifications in LCLs (ENCODE)Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE29611).
-
TF binding sites in LCLs (ENCODE)Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE31477).
Article and author information
Author details
Funding
National Cancer Institute (R01-CA140337)
- Micah A Luftig
American Cancer Society (RSG-13-228-01-MPC)
- Micah A Luftig
Wellcome (099273/Z/12/Z)
- Quentin Bazot
- Martin J Allday
National Institute for Dental and Cranofacial Research (R01-DE025994)
- Joanne Dai
- Micah A Luftig
National Institute for Allergy and Infectious Diseases (5P30-AI064518)
- Micah A Luftig
National Cancer Institute (F31-CA180451)
- Alexander M Price
National Institute for Dental and Cranofacial Research (R01-DE023939)
- Eric C Johannsen
National Institute for Allergy and Infectious Diseases (T32-AI078985)
- Reza Djavadian
National Cancer Institute (R01-CA129974)
- Anthony Letai
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Copyright
© 2017, Price et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 3,614
- views
-
- 720
- downloads
-
- 57
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Epstein-Barr virus ensures B cell survival by uniquely modulating apoptosis at early and late times after infection
eLife 6:e22509.
https://doi.org/10.7554/eLife.22509
Further reading
-
- Cancer Biology
Metastasis is the leading cause of cancer-related mortality. Paneth cells provide stem cell niche factors in homeostatic conditions, but the underlying mechanisms of cancer stem cell niche development are unclear. Here, we report that Dickkopf-2 (DKK2) is essential for the generation of cancer cells with Paneth cell properties during colon cancer metastasis. Splenic injection of Dkk2 knockout (KO) cancer organoids into C57BL/6 mice resulted in a significant reduction of liver metastases. Transcriptome analysis showed reduction of Paneth cell markers such as lysozymes in KO organoids. Single-cell RNA sequencing analyses of murine metastasized colon cancer cells and patient samples identified the presence of lysozyme positive cells with Paneth cell properties including enhanced glycolysis. Further analyses of transcriptome and chromatin accessibility suggested hepatocyte nuclear factor 4 alpha (HNF4A) as a downstream target of DKK2. Chromatin immunoprecipitation followed by sequencing analysis revealed that HNF4A binds to the promoter region of Sox9, a well-known transcription factor for Paneth cell differentiation. In the liver metastatic foci, DKK2 knockout rescued HNF4A protein levels followed by reduction of lysozyme positive cancer cells. Taken together, DKK2-mediated reduction of HNF4A protein promotes the generation of lysozyme positive cancer cells with Paneth cell properties in the metastasized colon cancers.
-
- Cancer Biology
- Computational and Systems Biology
This study investigates the variability among patients with non-small cell lung cancer (NSCLC) in their responses to immune checkpoint inhibitors (ICIs). Recognizing that patients with advanced-stage NSCLC rarely qualify for surgical interventions, it becomes crucial to identify biomarkers that influence responses to ICI therapy. We conducted an analysis of single-cell transcriptomes from 33 lung cancer biopsy samples, with a particular focus on 14 core samples taken before the initiation of palliative ICI treatment. Our objective was to link tumor and immune cell profiles with patient responses to ICI. We discovered that ICI non-responders exhibited a higher presence of CD4+ regulatory T cells, resident memory T cells, and TH17 cells. This contrasts with the diverse activated CD8+ T cells found in responders. Furthermore, tumor cells in non-responders frequently showed heightened transcriptional activity in the NF-kB and STAT3 pathways, suggesting a potential inherent resistance to ICI therapy. Through the integration of immune cell profiles and tumor molecular signatures, we achieved an discriminative power (area under the curve [AUC]) exceeding 95% in identifying patient responses to ICI treatment. These results underscore the crucial importance of the interplay between tumor and immune microenvironment, including within metastatic sites, in affecting the effectiveness of ICIs in NSCLC.
